Three patients are presented who developed reversible sensorineural hearing losses during treatment with intravenous erythromycin lactobionate. A fourth patient treated with erythromycin gluceptate did not develop hearing loss. Ototoxicity with erythromycin lactobionate has been previously reported in only three patients, one of whom had medication orally. Withdrawal of the antibiotic resulted in prompt improvement in every case with return of hearing to pretreatment levels.
Get full access to this article
View all access options for this article.
References
1.
MullerGGrossMGreenbergLA: The Salicylates. New Haven, Hillhouse Press, 1948, p 103
2.
MathogRHThomasWGHudsonWR: Ototoxicity of new and potent diuretics. Arch Otolaryngol20: 7–13, 1970
3.
BenitezJTSchuknechtHFBrandenburgJM: Pathologic changes in the human ear after kanamycin. Arch Otolaryngol75: 192–197, 1962
4.
MintzUAmirJPinkhasJ: Transient perceptive deafness due to erythromycin lactobionate. JAMA225: 1122–1123, 1973
5.
EckmanMJohnsonTReissR: Partial deafness after erythromycin. N Engl J Med292: 649, 1975
